Acorda Therapeutics Inc. said Rick Batycky is leaving as the company's chief technology officer, effective Aug. 20, to be the CEO of a privately held, venture-backed biotechnology company.
David Lawrence, chief of business operations, will take over the position for Acorda's Chelsea, Mass.-based manufacturing facility, which produces Inbrija, a drug indicated to treat symptoms of so-called off periods — times when the effects of a medication wears off — in Parkinson's disease. He will also handle the external manufacturing of Ampyra, a medication to help improve walking in adults with multiple sclerosis.
In addition, Chief Medical Officer Burkhard Blank will lead the company's pharmaceutical development and technical operations team.
Ardsley, N.Y.-based Acorda Therapeutics is a biopharmaceutical company that develops therapies to restore function and improve the lives of people with neurological disorders.